We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Beckman Coulter Life Sciences to Produce Automated Cytometry Systems

By LabMedica International staff writers
Posted on 23 Apr 2012
Beckman Coulter Life Sciences (Indianapolis, IN, USA) has increased the range of its products by acquiring Blue Ocean Biomedical (Pembroke Pines, FL, USA), a manufacturer of a line of automated flow cytometry systems and associated reagents.

Beckman Coulter develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing. More...
Their diagnostic systems are found in hospitals and other critical care settings around the world and generate data used by physicians to diagnose disease, make treatment decisions, and monitor patients. In the research sector, their instruments have been applied to complex biological problems including causes of disease and potential new therapies or drugs.

Blue Ocean Biomedical specializes in the development of innovative, automated “load & go” cell-analysis systems for immune monitoring and related applications. Blue Ocean has optimized their systems to address needs for specific moderate-to-high-demand applications where test results are desired in less time, with greater efficiency and at substantially lower costs.

The CR Series Systems are among Blue Ocean Biomedical’s top-of-the-line research tools. This instrument is a fully integrated, fluorescence-based, cellular analysis research system dedicated to running standardized immune monitoring panels. The design of the CR Series takes full advantage of advanced technology to introduce a fresh, innovative approach to automating the process of immune panel testing. The CR Series combines automated sample preparation - “load & go”- sample processing and analysis in one compact instrument.

“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president of Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We will be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”

“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”

The CR systems and reagents are currently not available in the US, and are for distribution in the European Union only.

Related Links:
Beckman Coulter Life Sciences
Blue Ocean Biomedical


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.